Price T Rowe Associates Inc Immunity Bio, Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 75,247 shares of IBRX stock, worth $383,759. This represents 0.0% of its overall portfolio holdings.
Number of Shares
75,247
Previous 130,761
42.45%
Holding current value
$383,759
Previous $828,000
66.06%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding IBRX
# of Institutions
204Shares Held
70MCall Options Held
1.68MPut Options Held
1.31M-
Vanguard Group Inc Valley Forge, PA16.9MShares$86.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$58.3 Million0.0% of portfolio
-
State Street Corp Boston, MA8.65MShares$44.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.85MShares$19.6 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.25MShares$11.5 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $2.04B
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...